Sugi Predict

Sugi Predict / Compounds / SCHEMBL21884641

SCHEMBL21884641

SCHEMBL21884641

N#Cc1ccc(O)c(C(=O)NC(=N)N)c1-c1cc(Cl)ccc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TMPRSS4 Q9NRS4 5/20 0.40
▸ S1PR3 Q99500 6/20 0.37
▸ P2RX1 P51575 5/20 0.37
▸ PPIA P62937 1/20 0.36
▸ S1PR1 P21453 2/20 0.36
▸ TAS1R3 Q7RTX0 1/20 0.35
▸ TAS1R1 Q7RTX1 1/20 0.35
▸ TAS1R2 Q8TE23 1/20 0.35
▸ ADRA1D P25100 1/20 0.35
▸ P2RX4 Q99571 2/20 0.34
▸ P2RX7 Q99572 2/20 0.34
▸ F2 P00734 1/20 0.34
▸ F10 P00742 1/20 0.34
▸ PLG P00747 1/20 0.34
▸ PLAU P00749 1/20 0.34
▸ PLAT P00750 1/20 0.34
▸ KCNQ3 O43525 1/20 0.34
▸ KCNQ2 O43526 1/20 0.34
▸ KCNE1 P15382 1/20 0.34
▸ KCNQ1 P51787 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21884418 0.93 S1PR3 (0.37) TMPRSS4S1PR3P2RX1PPIAS1PR1
SCHEMBL23854851 0.90 PPIA (0.36) S1PR3P2RX1PPIATAS1R3TAS1R1
SCHEMBL21884530 0.90 TMPRSS4 (0.40) TMPRSS4S1PR3P2RX1PPIAADRA1D
SCHEMBL21884534 0.88 PPIA (0.35) S1PR3PPIAS1PR1F2F10
SCHEMBL21884361 0.86 PPIA (0.39) TMPRSS4P2RX1PPIAP2RX4P2RX7
SCHEMBL21884458 0.85 S1PR3 (0.37) S1PR3S1PR1F2F10PLAU
SCHEMBL21884581 0.85 KCNMA1 (0.42) TMPRSS4S1PR3S1PR1F10
SCHEMBL21884788 0.85 PPIA (0.40) PPIA
SCHEMBL21885702 0.84 PPIA (0.35) TMPRSS4S1PR3P2RX1PPIATAS1R3
SCHEMBL21884443 0.84 PPIA (0.38) S1PR3P2RX1PPIA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS INC. 2021-12-02 — — US disclosed
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS INC. 2021-12-02 — — US disclosed
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY JNANA THERAPEUTICS INC. 2021-09-30 — — US disclosed
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY JNANA THERAPEUTICS INC. 2021-09-30 — — US disclosed
WO-2020061473-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS, INC. (US) 2020-03-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY SLC19A1, SLC1A5, SLC1A2 TMPRSS4 1380/4885S1PR3 1595/4885P2RX1 3206/4885
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS SNRPE, G3BP1, G3BP2 TMPRSS4 3136/4885S1PR3 3963/4885P2RX1 4811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.